COR Stock Recent News

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J. , July 15, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced the execution of a distribution services agreement with Cencora (formerly AmerisourceBergen), a global pharmaceutical services company.

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chie.

VANCOUVER, BC / ACCESS Newswire / June 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce high‐grade copper channel results from the Katty prospect located in the Diva Trend, one of several prospective targets at the Company's Los Chapitos Copper Project ("Los Chapitos" or the "Project") in Peru. A total of 12 excavated channels were completed at the prospect and all channels contained significant high-grade intercepts of copper with associated silver (Table 1).

VANCOUVER, BC / ACCESS Newswire / June 5, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce the receipt of CAD$1.5 million from exploration partner Nittetsu Mining CO., Ltd. ("Nittetsu") to fully fund the upcoming exploration and drilling campaign at Camino's Los Chapitos Copper Project ("Los Chapitos" or the "Project") in Peru.

Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. “Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value,” said Mark Du.

Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can distribute. Future share price targets point to significant potential upside over 3 years, justifying a buy despite the stock trading above average now.